Provention Bio, Inc. (PRVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRVB POWR Grades
- Growth is the dimension where PRVB ranks best; there it ranks ahead of 69.98% of US stocks.
- PRVB's strongest trending metric is Stability; it's been moving down over the last 179 days.
- PRVB's current lowest rank is in the Stability metric (where it is better than 6.87% of US stocks).
PRVB Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for PRVB is 0.01 -- better than merely 7.21% of US stocks.
- For PRVB, its debt to operating expenses ratio is greater than that reported by merely 5.43% of US equities we're observing.
- PRVB's price/sales ratio is 348.45; that's higher than the P/S ratio of 98.93% of US stocks.
- Stocks that are quantitatively similar to PRVB, based on their financial statements, market capitalization, and price volatility, are CRDF, BLDP, RDCM, VERU, and CYTK.
- PRVB's SEC filings can be seen here. And to visit Provention Bio Inc's official web site, go to www.proventionbio.com.
PRVB Valuation Summary
- 500 - Internal server error
- PRVB's price/earnings ratio has moved up 13.8 over the prior 38 months.
- PRVB's price/earnings ratio has moved up 13.8 over the prior 38 months.
Below are key valuation metrics over time for PRVB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PRVB | 2021-08-31 | NA | 2.7 | -3.4 | -2.2 |
| PRVB | 2021-08-30 | NA | 2.6 | -3.3 | -2.1 |
| PRVB | 2021-08-27 | NA | 2.6 | -3.3 | -2.1 |
| PRVB | 2021-08-26 | NA | 2.5 | -3.2 | -2.0 |
| PRVB | 2021-08-25 | NA | 2.6 | -3.3 | -2.1 |
| PRVB | 2021-08-24 | NA | 2.5 | -3.2 | -1.9 |
PRVB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PRVB has a Quality Grade of D, ranking ahead of 10.75% of graded US stocks.
- PRVB's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows PRVB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | NA | -12.020 |
| 2021-03-31 | 0 | NA | -9.077 |
| 2020-12-31 | 0 | NA | -5.010 |
| 2020-09-30 | 0 | NA | -2.755 |
| 2020-06-30 | 0 | NA | -2.434 |
| 2020-03-31 | 0 | NA | -2.583 |
PRVB Price Target
For more insight on analysts targets of PRVB, see our PRVB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.93 | Average Broker Recommendation | 1.5 (Moderate Buy) |
PRVB Stock Price Chart Interactive Chart >
PRVB Price/Volume Stats
| Current price | $3.91 | 52-week high | $9.35 |
| Prev. close | $3.96 | 52-week low | $3.40 |
| Day low | $3.78 | Volume | 408,352 |
| Day high | $3.94 | Avg. volume | 797,956 |
| 50-day MA | $4.31 | Dividend yield | N/A |
| 200-day MA | $5.76 | Market Cap | 250.40M |
Provention Bio, Inc. (PRVB) Company Bio
Provention Bio, Inc. operates as a biopharmaceutical company. The Company focuses on development of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Provention Bio serves patients in the State of New Jersey.
Latest PRVB News From Around the Web
Below are the latest news stories about Provention Bio Inc that investors may wish to consider to help them evaluate PRVB as an investment opportunity.
Provention Bio, Inc's. (PRVB) CEO Ashleigh Palmer on Q4 2021 Results - Earnings Call TranscriptProvention Bio, Inc. (PRVB) Q4 2021 Earnings Conference Call February 24, 2022, 08:00 AM ET Company Participants Robert Doody - VP, IR Ashleigh Palmer - Co-Founder, President, CEO Francisco Leon - Co-Founder & Chief Scientific Officer Jason Hoitt - Chief Commercial Officer Thierry Chauche - Chief Financial Officer Conference Call... |
Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue EstimatesProvention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateProvention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update. |
Provention Bio Q4 2021 Earnings PreviewProvention Bio (NASDAQ:PRVB) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.46 (+20.7% Y/Y) and the consensus Revenue Estimate is $0.47M Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward.... |
Provention Bio resubmits marketing application for diabetes drug in U.S.The clinical-stage biopharmaceutical company, Provention Bio (PRVB), is trading ~5% higher in the pre-market after the company announced the resubmission of its marketing application |
PRVB Price Returns
| 1-mo | N/A |
| 3-mo | -46.58% |
| 6-mo | -30.43% |
| 1-year | -53.78% |
| 3-year | -67.69% |
| 5-year | N/A |
| YTD | -30.43% |
| 2021 | -66.82% |
| 2020 | 13.69% |
| 2019 | 741.81% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...